Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024
Daxor (NASDAQ: DXR), a leader in blood volume measurement technology, announces its participation in the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024. The event, scheduled for September 27-30 in Atlanta, will feature Daxor's Blood Volume Analysis (BVA) technology. Key highlights include:
1. Exclusive BVA showcase in the 'Devices in Heart Failure' session
2. Product presentation in the main Exhibit Hall
3. Corporate Member Meeting with HFSA leadership
Daxor's CEO emphasizes the importance of BVA in personalizing treatment and improving patient outcomes. BVA-guided treatment has shown significant reductions in heart failure readmissions, mortality rates, and hospital stays. Daxor will be exhibiting at Booth 225 during the conference.
Daxor (NASDAQ: DXR), un leader nella tecnologia di misurazione del volume sanguigno, annuncia la sua partecipazione al Congresso Scientifico Annuale della Heart Failure Society of America (HFSA) 2024. L'evento, in programma dal 27 al 30 settembre ad Atlanta, presenterà la tecnologia di Analisi del Volume Sanguigno (BVA) di Daxor. I punti salienti includono:
1. Vetrina esclusiva della BVA nella sessione 'Dispositivi nell'Insufficienza Cardiaca'
2. Presentazione del prodotto nel principale Hall Espositiva
3. Riunione dei Soci Aziendali con la leadership dell'HFSA
Il CEO di Daxor sottolinea l'importanza della BVA nella personalizzazione dei trattamenti e nel miglioramento dei risultati per i pazienti. Il trattamento guidato dalla BVA ha mostrato riduzioni significative nei ricoveri per insufficienza cardiaca, nei tassi di mortalità e nella durata della degenza ospedaliera. Daxor esporrà allo Stand 225 durante la conferenza.
Daxor (NASDAQ: DXR), un líder en tecnología de medición del volumen sanguíneo, anuncia su participación en el Congreso Científico Anual de la Sociedad de Insuficiencia Cardíaca de América (HFSA) 2024. El evento, programado del 27 al 30 de septiembre en Atlanta, presentará la tecnología de Análisis del Volumen Sanguíneo (BVA) de Daxor. Los aspectos destacados incluyen:
1. Exhibición exclusiva de BVA en la sesión 'Dispositivos en la Insuficiencia Cardíaca'
2. Presentación del producto en el Hall Principal de Exposiciones
3. Reunión de Miembros Corporativos con los líderes de HFSA
El CEO de Daxor enfatiza la importancia de la BVA para personalizar los tratamientos y mejorar los resultados de los pacientes. El tratamiento guiado por BVA ha demostrado reducciones significativas en las readmisiones por insuficiencia cardíaca, tasas de mortalidad y estancias hospitalarias. Daxor tendrá un stand en el 225 durante la conferencia.
Daxor (NASDAQ: DXR), 혈액량 측정 기술의 선두주자가 미국심부전학회(HFSA) 2024년 연례 과학 회의에 참가한다고 발표했습니다. 9월 27일부터 30일까지 애틀랜타에서 열리는 이번 이벤트에서 Daxor의 혈액량 분석(BVA) 기술이 소개될 것입니다. 주요 하이라이트는 다음과 같습니다:
1. '심부전에서의 장치' 세션에서의 독점 BVA 전시
2. 주요 전시 홀에서의 제품 발표
3. HFSA 리더십과의 기업 회원 회의
Daxor의 CEO는 치료를 개인화하고 환자 결과를 개선하는 데 있어 BVA의 중요성을 강조합니다. BVA 기반 치료는 심부전 재입원, 사망률 및 병원 체류 기간을 크게 줄이는 것으로 나타났습니다. Daxor는 컨퍼런스 동안 225번 부스에서 전시할 것입니다.
Daxor (NASDAQ: DXR), un leader dans la technologie de mesure du volume sanguin, annonce sa participation à la Réunion Scientifique Annuelle de la Heart Failure Society of America (HFSA) 2024. L'événement, prévu du 27 au 30 septembre à Atlanta, mettra en avant la technologie d'Analyse du Volume Sanguin (BVA) de Daxor. Les points forts incluent :
1. Présentation exclusive de la BVA lors de la session 'Dispositifs en Insuffisance Cardiaque'
2. Présentation du produit dans le Hall d'Exposition principal
3. Réunion des membres corporatifs avec la direction de l'HFSA
Le PDG de Daxor souligne l'importance de la BVA dans la personnalisation des traitements et l'amélioration des résultats pour les patients. Les traitements guidés par la BVA ont montré des réductions significatives des réhospitalisations pour insuffisance cardiaque, des taux de mortalité et des durées de séjour à l'hôpital. Daxor exposera au Stand 225 durant la conférence.
Daxor (NASDAQ: DXR), ein führendes Unternehmen in der Technologie zur Messung des Blutvolumens, kündigt seine Teilnahme am Jahrestreffen der Heart Failure Society of America (HFSA) 2024 an. Die Veranstaltung findet vom 27. bis 30. September in Atlanta statt und wird die Technologie zur Blutvolumenanalyse (BVA) von Daxor präsentieren. Zu den wichtigsten Punkten gehören:
1. Exklusive BVA-Präsentation in der Sitzung 'Geräte bei Herzinsuffizienz'
2. Produktpräsentation in der Hauptausstellungsfläche
3. Treffen der Unternehmensmitglieder mit der HFSA-Leitung
Der CEO von Daxor betont die Bedeutung der BVA für die Personalisierung der Behandlung und die Verbesserung der Patientenergebnisse. BVA-gestützte Behandlungen haben signifikante Reduzierungen bei den Wiederaufnahmen wegen Herzinsuffizienz, Sterblichkeitsraten und Krankenhausaufenthalten gezeigt. Daxor wird während der Konferenz am Stand 225 ausstellen.
- Daxor's BVA technology to be showcased at a major heart failure conference
- BVA-guided treatment reduces 30-day heart failure readmissions by 56%
- BVA-guided treatment reduces 30-day mortality by 82% and 1-year mortality by 86%
- BVA-guided treatment results in a 57% reduction in hospital length of stay
- None.
Oak Ridge, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces its participation in the Annual Scientific Meeting of the Heart Failure Society of America (HFSA), taking place September 27-30 at the Georgia World Congress Center and Signia by Hilton Atlanta. The event will gather the world’s top heart failure experts.
Key meeting highlights:
- Exclusive showcase of BVA at the HFSA 'Devices in Heart Failure: From Mechanisms to Implementation' session.
- Presentation of products and services in the main Exhibit Hall.
- Corporate Member Meeting with HFSA leadership.
“We're excited to showcase how our BVA technology provides precise, actionable data, enabling clinicians to personalize treatment for both inpatient and outpatient care," said Michael Feldschuh, CEO and President of Daxor Corporation. "By equipping healthcare providers with innovative diagnostic tools for informed decision-making, we aim to enhance patient outcomes and drive long-term improvements in heart failure treatment and reduce overall costs."
BVA guided treatment in heart failure has shown to reduce heart failure 30-day readmissions by
The company will be exhibiting at Booth 225.
Register for HFSA2024.
About Daxor Corporation
Daxor Corporation (NASDAQ: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
When and where is Daxor (DXR) participating in the HFSA Annual Scientific Meeting 2024?
What are the key highlights of Daxor's (DXR) participation in the HFSA 2024 meeting?
What are the reported benefits of Daxor's (DXR) BVA-guided treatment for heart failure patients?
Where can attendees find Daxor (DXR) at the HFSA 2024 conference?
